Takeda’s TAK-442 Enters Phase II Development

November 6, 2007

Japan drugmaker Takeda Pharmaceutical’s investigational compound TAK-442 has entered Phase II studies in the U.S. and Europe.

TAK-442 is a novel Factor Xa inhibitor developed by Takeda.

Factor Xa (FXa) plays a role in the blood coagulation cascade. Inhibition of FXa is expected to result in interruption of either venous or arterial thromboembolism, Takeda said.